PROVIDENCE, R.I., Sept. 3, 2026 /PRNewswire/ -- EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the immunogenicity risk of biotherapeutics. The release introduces an updated JanusMatrix™ model, a refined tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody (ADA) prediction model designed to provide deeper insight into immunogenicity risk. For decades, EpiVax has pioneered computational immunology through the development of advanced in silico algorithms for evaluating biother…READ FULL ARTICLE
